Adverse events148

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 148

Type	Event	Organ system	Group	Affected	At risk
other	Nausea	Gastrointestinal disorders	Induction Phase: Rapid Induction	65	474
other	Nausea	Gastrointestinal disorders	Induction Phase: Standard of Care Induction	31	255
other	Nausea	Gastrointestinal disorders	Maintenance Phase: Extended-release Buprenorphine 100 mg	0	218
other	Nausea	Gastrointestinal disorders	Maintenance Phase: Extended-release Buprenorphine 300 mg	0	217
other	Vomiting	Gastrointestinal disorders	Induction Phase: Rapid Induction	32	474
other	Vomiting	Gastrointestinal disorders	Induction Phase: Standard of Care Induction	15	255
other	Vomiting	Gastrointestinal disorders	Maintenance Phase: Extended-release Buprenorphine 100 mg	0	218
other	Vomiting	Gastrointestinal disorders	Maintenance Phase: Extended-release Buprenorphine 300 mg	0	217
other	Anxiety	Psychiatric disorders	Induction Phase: Rapid Induction	50	474
other	Anxiety	Psychiatric disorders	Induction Phase: Standard of Care Induction	21	255
other	Anxiety	Psychiatric disorders	Maintenance Phase: Extended-release Buprenorphine 100 mg	0	218
other	Anxiety	Psychiatric disorders	Maintenance Phase: Extended-release Buprenorphine 300 mg	0	217
other	Restlessness	Psychiatric disorders	Induction Phase: Rapid Induction	33	474
other	Restlessness	Psychiatric disorders	Induction Phase: Standard of Care Induction	14	255
other	Restlessness	Psychiatric disorders	Maintenance Phase: Extended-release Buprenorphine 100 mg	0	218
other	Restlessness	Psychiatric disorders	Maintenance Phase: Extended-release Buprenorphine 300 mg	0	217
other	Hyperhidrosis	Skin and subcutaneous tissue disorders	Induction Phase: Rapid Induction	26	474
other	Hyperhidrosis	Skin and subcutaneous tissue disorders	Induction Phase: Standard of Care Induction	11	255
other	Hyperhidrosis	Skin and subcutaneous tissue disorders	Maintenance Phase: Extended-release Buprenorphine 100 mg	0	218
other	Hyperhidrosis	Skin and subcutaneous tissue disorders	Maintenance Phase: Extended-release Buprenorphine 300 mg	0	217

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04995029/events

API reference For AI assistants

Adverse events148

Sources 3

Read this list from software.